EPCAM and liver cancer: CD133 and EpCAM have been regarded as surface markers of tumor initiating cells or tumor‐initiating cells in liver cancer.[24, 25, 26] Consistently, both proportions of CD133 and EpCAM were significantly increased in Huh7 and HepG2 cell lines, and patient‐derived cells (PDCs) in response to glutamine deprivation for 2 days (Figure 1H; Figure S1D, Supporting Information).